Platelet-Derived Mitochondria Display Embryonic Stem Cell Markers and Improve Pancreatic Islet β-cell Function in...

Area of Science:

• Immunology
• Endocrinology
• Regenerative Medicine

Background:

• Diabetes mellitus, including type 1 (T1D) and type 2 (T2D), is a growing global health concern.
• Overcoming immune dysfunction and pancreatic islet beta-cell loss remains a significant challenge in diabetes research.
• Previous studies indicated Stem Cell Educator (SCE) therapy is safe and effective for autoimmune diseases.

Purpose of the Study:

• To evaluate the long-term safety and clinical efficacy of SCE therapy in patients with T1D and T2D.
• To elucidate the underlying mechanisms of SCE therapy in diabetes treatment.
• To investigate the role of platelets and their mitochondria in diabetes after SCE therapy.

Main Methods:

• Four-year follow-up studies were conducted on patients undergoing SCE therapy.
• Mechanistic studies analyzed the modulation of platelets and immune cells post-therapy.
• Ex vivo studies examined the interaction of platelet-derived mitochondria with human pancreatic islets.

Main Results:

• SCE therapy demonstrated sustained safety and clinical efficacy in T1D and T2D patients over four years.
• Platelets in treated patients exhibited altered immune tolerance markers.
• Platelet-derived mitochondria were observed to enhance pancreatic islet beta-cell proliferation and function.

Conclusions:

• SCE therapy offers a promising long-term treatment for type 1 and type 2 diabetes.
• The therapy's mechanism involves platelet modulation of immune responses and direct enhancement of pancreatic islet beta-cell function via mitochondria.
• These findings present novel therapeutic strategies for diabetes.